TRIDENT LIFELINE
|
TRIDENT LIFELINE Last 5 Year Financial Ratios History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | |
---|---|---|---|
Operational & Financial Ratios | |||
Earnings Per Share (Rs) | 5.52 | 5.23 | 4.93 |
CEPS(Rs) | 6.01 | 5.55 | 5.19 |
DPS(Rs) | - | - | - |
Book NAV/Share(Rs) | 43.43 | 39.11 | 5.93 |
Tax Rate(%) | 31.69 | 8.57 | -32.31 |
Margin Ratios | |||
Core EBITDA Margin(%) | 18.45 | 19.77 | 12.44 |
EBIT Margin(%) | 20.94 | 22.29 | 14.28 |
Pre Tax Margin(%) | 19.48 | 20.77 | 13.71 |
PAT Margin (%) | 13.31 | 18.99 | 18.14 |
Cash Profit Margin (%) | 15.48 | 20.14 | 19.07 |
Performance Ratios | |||
ROA(%) | 7.92 | 16.00 | 30.72 |
ROE(%) | 12.52 | 24.21 | 83.23 |
ROCE(%) | 15.32 | 23.60 | 43.21 |
Asset Turnover(x) | 0.60 | 0.84 | 1.69 |
Sales/Fixed Asset(x) | 3.26 | 9.68 | 9.76 |
Working Capital/Sales(x) | 1.41 | 0.84 | 7.03 |
Efficiency Ratios | |||
Fixed Capital/Sales(x) | 0.31 | 0.10 | 0.10 |
Receivable days | 104.41 | 98.21 | 83.27 |
Inventory Days | 80.77 | 62.65 | 62.24 |
Payable days | 90.79 | 111.70 | 177.25 |
Valuation Parameters | |||
PER(x) | 29.71 | 30.41 | - |
PCE(x) | 27.28 | 28.66 | - |
Price/Book(x) | 3.77 | 4.07 | - |
Yield(%) | - | - | - |
EV/Net Sales(x) | 4.49 | 5.58 | 0.47 |
EV/Core EBITDA(x) | 19.42 | 23.81 | 3.11 |
EV/EBIT(x) | 21.43 | 25.04 | 3.31 |
EV/CE(x) | 2.89 | 3.36 | 0.80 |
M Cap / Sales | 4.22 | 5.77 | - |
Growth Ratio | |||
Net Sales Growth(%) | 40.82 | 45.59 | - |
Core EBITDA Growth(%) | 38.82 | 124.29 | - |
EBIT Growth(%) | 32.26 | 127.18 | - |
PAT Growth(%) | -1.31 | 52.46 | - |
EPS Growth(%) | 5.46 | 6.01 | - |
Financial Stability Ratios | |||
Total Debt/Equity(x) | 0.37 | 0.17 | 0.52 |
Current Ratio(x) | 2.51 | 4.18 | 1.41 |
Quick Ratio(x) | 1.91 | 3.57 | 0.92 |
Interest Cover(x) | 14.42 | 14.67 | 24.72 |
Total Debt/Mcap(x) | 0.10 | 0.04 | - |
Compare Financial Ratios of peers of TRIDENT LIFELINE
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
TRIDENT LIFELINE | ₹316.3 Cr | -3.5% | -11.5% | 37.4% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹433,920.0 Cr | -0.1% | 1.7% | 45.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹155,160.0 Cr | -0.1% | -2.2% | 56.9% | Stock Analytics | |
CIPLA | ₹118,917.0 Cr | 1.7% | 0.5% | 23.7% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹112,017.0 Cr | 5.7% | 12.4% | 18.5% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹97,997.1 Cr | -1.4% | 3.1% | 44.8% | Stock Analytics |
TRIDENT LIFELINE Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
TRIDENT LIFELINE | -3.5% |
-11.5% |
37.4% |
SENSEX | -5% |
0.6% |
9.2% |
You may also like the below Video Courses